switching between glp-1 agonists chart Schematic illustration of monoagonists, dual and triple Switching between GLP‐1 receptor agonists

How GLP-1 and GIP pathways work, why dual-action tirzepatide (Mounjaro) differs from GLP-1-only medicines, and what trial averages mean for UK patients.

Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP1-based obesity pharmacotherapy.

GLP-1 medications can provide major health benefits, but recent studies have raised questions about a possible link with NAION, a rare optic nerve condition that can cause sudden vision loss

Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality

Supports gut lining integrity

Although these mechanisms have been exploited to facilitate weight loss, these medications have also been indicated for patients with cardiovascular or renal diseases, all of which have caused a recent drastic rise in prescribing GLP-1 RAs